Evidence map›Paper›PMID 41024759›Full record

ReviewWorld journal of gastroenterology2025

Explainable artificial intelligence for personalized management of inflammatory bowel disease: A minireview of recent advances.

Uchenna E Okpete, Haewon Byeon

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Uchenna E OkpeteDepartment of Digital Anti-aging Healthcare, Inje University, Gimhae 50834, South Korea.
Haewon ByeonWorker's Care and Digital Health Lab, Department of Future Technology, Korea University of Technology and Education, Cheonan 31253, South Korea. bhwpuma@naver.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized management of inflammatory bowel disease (IBD) is crucial due to the heterogeneity in disease presentation, variable therapeutic response, and the unpredictable nature of disease progression. Although artificial intelligence (AI) and machine learning algorithms offer promising solutions by analyzing complex, multidimensional patient data, the "black-box" nature of many AI models limits their clinical adoption. Explainable AI (XAI) addresses this challenge by making data-driven predictions more transparent and clinically actionable. This minireview focuses on recent advancements and clinical relevance of integrating XAI for personalized IBD management. We explore the importance of XAI in prioritizing treatment and highlight how XAI techniques, such as feature-attribution explanations and interpretable model architectures, enhance transparency in AI models. In recent years, XAI models have been applied to diagnose IBD anomalies by prioritizing the predictive features for gastrointestinal bleeding and dietary intake patterns. Furthermore, studies have revealed that XAI application enhances IBD risk stratification and improves the prediction of drug efficacy and patient responses with high accuracy. By transforming opaque AI models into interpretable tools, XAI fosters clinician trust, supports personalized decision-making, and enables the safe deployment of AI systems in sensitive, individualized IBD care pathways.

Indexed as

Artificial IntelligenceInflammatory Bowel DiseasesPrecision MedicineClinical Decision-MakingGastrointestinal HemorrhageHumansMachine LearningRisk AssessmentClinical decision-makingCrohn’s diseaseFeature attributionHeterogeneous populationInterpretabilityMachine learningPrecision medicineUlcerative colitis

Identifiers

PMID41024759
PMCPMC12476648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.